Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Core Insights - Fennec Pharmaceuticals reported first quarter 2025 total net revenues of $8.8 million, representing an 18$7.4 million in the first quarter of 2024 [1][5][10] - The company has successfully launched PEDMARQSI in Germany and the United Kingdom, enhancing access to its product for cancer patients at risk of hearing loss [1][6][29] - The revamped Fennec HEARS™ patient support program aims to improve the experience for adolescent and young adult cancer patients [2][6] Financial Results - Net product sales for the first quarter of 2025 were approximately $8.8 million, up from$7.4 million in the same period last year [5][10] - Total revenue for the first quarter was $8.8 million, with no licensing revenue recorded compared to$17.96 million in the first quarter of 2024 [10] - Operating expenses totaled $9.56 million, down from$11.63 million in the previous year, with selling and marketing expenses decreasing to $2.95 million from$5.21 million [11][10] Business Highlights - The company has strengthened its segmentation model and data-driven target lists, leading to the addition of multiple new accounts across academic and community providers [6][7] - The commercial launch of PEDMARQSI in Europe marks a significant step in expanding access to the product [6][29] - Fennec will participate in the ASCO 2025 Annual Meeting and other investor conferences, indicating ongoing engagement with the medical and investment communities [6][4] Upcoming Events - Fennec will host a conference call on May 13, 2025, at 8:30 a.m. ET to discuss its financial results and business updates [1][8] - The Annual General Meeting is scheduled for June 3, 2025, in New York, providing an opportunity for shareholder engagement [6][4]